International forum of allergy & rhinology · 2026
Chronic Rhinosinusitis With Nasal Polyposis in EGPA: A Real-Life Multidimensional Analysis Through Mepolizumab Dosing and Role of Adjunctive Endoscopic Sinus Surgery (ESS).
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Howardson Bright Oworae, Danè Giulia, Moroni Luca, Lanzillotta Marco, Tanzini Umberto, Gallina Gabriele D, Cariddi Adriana, Venerandi Biancamaria, Dagna Lorenzo, Giordano Leone, Karligkiotis Apostolos
Аннотация
BACKGROUND: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare necrotizing vasculitis involving upper- and lower-airways. Despite biologics, sinonasal disease often persists. Evidence on ENT trajectories under anti-IL5 treatment and role of endoscopic sinus surgery (ESS) remains limited and is often described without standardized assessment tools. This study provides a systematic, multidimensional evaluation of sinonasal outcomes under biologic therapy and analyzes the role of ESS in a real-life cohort.
METHODS: We retrospectively analyzed 52 EGPA patients with a 24-month follow-up on mepolizumab. Sinonasal disease was assessed by Nasal Polyp Score (NPS), Lund-Kennedy Score (LKS), Lund-Mackay score (LMK), and SNOT-22, while systemic activity was assessed by Birmingham Vasculitis Activity Score (BVAS). Patients were stratified by mepolizumab regimen (100 mg, 300 mg, and step-down). Predictors of adjunctive ESS were explored through multivariate logistic regression.
RESULTS: Systemic remission occurred in >90% of patients, with marked eosinophil suppression (median 700 → 59.5 cells/µL) and BVAS = 0. Conversely, NPS and LKS remained stable [IQR]: (NPS 4 [3-5] → 4 [2-5]; LKS 6 [4-8] → 5 [2-7.75]. Polyps persisted in 64% and mucosal edema/discharge in 92% of population. Continuous 100 mg therapy showed the greatest endoscopic improvement. Higher baseline sinonasal burden, more extensive surgical history, and mepolizumab dose variation were associated with adjunctive ESS (28.8%), whereas BVAS and eosinophils showed no correlation with ENT severity.
CONCLUSION: Sinonasal disease may persist despite systemic remission, suggesting a partially independent inflammatory niche. Comprehensive assessment should combine systemic markers with dedicated ENT evaluation, while management may require integrated biologic-surgical strategies in chronic structural disease.
METHODS: We retrospectively analyzed 52 EGPA patients with a 24-month follow-up on mepolizumab. Sinonasal disease was assessed by Nasal Polyp Score (NPS), Lund-Kennedy Score (LKS), Lund-Mackay score (LMK), and SNOT-22, while systemic activity was assessed by Birmingham Vasculitis Activity Score (BVAS). Patients were stratified by mepolizumab regimen (100 mg, 300 mg, and step-down). Predictors of adjunctive ESS were explored through multivariate logistic regression.
RESULTS: Systemic remission occurred in >90% of patients, with marked eosinophil suppression (median 700 → 59.5 cells/µL) and BVAS = 0. Conversely, NPS and LKS remained stable [IQR]: (NPS 4 [3-5] → 4 [2-5]; LKS 6 [4-8] → 5 [2-7.75]. Polyps persisted in 64% and mucosal edema/discharge in 92% of population. Continuous 100 mg therapy showed the greatest endoscopic improvement. Higher baseline sinonasal burden, more extensive surgical history, and mepolizumab dose variation were associated with adjunctive ESS (28.8%), whereas BVAS and eosinophils showed no correlation with ENT severity.
CONCLUSION: Sinonasal disease may persist despite systemic remission, suggesting a partially independent inflammatory niche. Comprehensive assessment should combine systemic markers with dedicated ENT evaluation, while management may require integrated biologic-surgical strategies in chronic structural disease.